ZymoGenetics deal for rThrombin hits a hurdle

ZymoGenetics' recent deal with Bayer HealthCare to market its new blood-clotting agent rThrombin has hit a snag. The company says that the FDA is considering its request for more manufacturing information as a major amendment to the application, which will push back final approval for the therapy. The FDA review now won't be completed until mid-January, three months later than anticipated. That marketing pact is worth up to $198 million and none of the $40 million in milestones outlined in the deal can now flow this year.

- read the report from The Street

Related Articles:
ZymoGenetics inks $198M deal. Report
Pivotal Thrombin trial a success for ZymoGenetics. Report
ZymoGenetics builds cash reserves as it advances Thrombin. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.